Biotin (vitamin B7) supplementation may offer protection against manganese-induced brain cell damage, according to a recent study. Manganese is a naturally occurring metal that can cause manganism, a condition characterized by parkinsonism-like symptoms, such as tremors and cognitive issues. In the study led by Souvarish Sarkar, PhD, an assistant…
Researchers at the University of Cambridge in the U.K. are developing brain implants using small clusters of lab-grown cells in combination with electrical impulses to rebuild brain circuits worn down in Parkinson’s disease. “Our ultimate goal is to create precise brain therapies that can restore normal brain function in…
Levels of a retrovirus that entered the human genome via infections millions of years ago — an endogenous retrovirus called HERV-K that is still part of a person’s DNA — were lower in people with Parkinson’s disease and linked to more severe symptoms and longer disease duration, a study…
Aging microglia, the immune cells of the brain that protect it by fighting infections and clearing debris, may mount a weaker immune response than younger microglia, according to a study that used lab-grown cells collected from mouse pups. Although both young and old microglia react to inflammation, they appear to…
Approximately two-thirds of Parkinson’s disease patients may experience paranoia and unusual sensations, including visual hallucinations, according to a new study from the U.K. People with Parkinson’s may have paranoid thoughts or unfounded fears, as well as abnormal sensory experiences, the study found. Further, many of the individuals who had…
U.S. researchers have identified, as a potential therapeutic target in Parkinson’s disease, a protein that controls part of the function of LRRK2 — a protein known to be overactive in Parkinson’s, including in patients without mutations in its coding gene. This discovery, made using cell and mouse models of…
C2N Diagnostics and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to study how Parkinson’s disease and similar neurodegenerative conditions overlap with Alzheimer’s disease. With a grant in the amount of more than $1.5 million from MJFF, researchers at C2N will identify and…
A mobile application that detects a person’s natural walking pace and provides real-time, beat-synchronized music for at-home rehabilitation improved walking in Parkinson’s disease patients, both during daily activities and in tests without music cues, a study found. The study, “Gait ecological assessment in persons with Parkinson’s disease engaged…
Aspen Neuroscience has completed dosing the first two groups of patients in ASPIRO, an ongoing Phase 1/2a clinical trial that’s testing the safety and tolerability of ANPD001, an investigational cell therapy for Parkinson’s disease. Patients with moderate to severe Parkinson’s who have so far received ANPD001, which uses…
BlueRock Therapeutics said it is progressing its investigational cell therapy, bemdaneprocel, into a Phase 3 clinical trial set to begin in the first half of 2025. The trial, named exPDite-2, will assess the safety and efficacy of the treatment for moderate Parkinson’s disease. This decision comes after positive…
Get regular updates to your inbox.
